Income Statement IntegraGen

Stocks

ALINT

FR0010908723

Biotechnology & Medical Research

Market Closed - Euronext Paris 18:55:00 30/09/2026 +03			5-day change	1st Jan Change
0.0706 ^EUR	0.00%		-4.34%	-46.92%

09-11	ABL Diagnostics Société anonyme proposed to acquire Business operations and assets of IntegraGen SA.	CI
09-11	ABL Diagnostics Offers to Acquire IntegraGen Amid Reorganization Proceedings	MT

d3be4db67e9d9b334e35.01UVDV_IgGNb6HYU6hpY8gAdL_2SUhuyRNrA72xEk84.mWUlUg-47xFqgUFNjmMOmUowTLfUf1zoAJywuz8C-6egDUBqcoTkBWOlIw

Published financial data: INTEGRAGEN

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2016 (EUR)	2017 (EUR)	2018 (EUR)	2019 (EUR)	2020 (EUR)
Revenues	6.02M	6.25M	6.92M	8.28M	9M
Other Revenues, Total	250K	261K	29K	1	-
Total Revenues	6.27M	6.51M	6.95M	8.28M	9M
Cost of Goods Sold, Total	4.52M	5.25M	4.55M	4.72M	3.28M
Gross Profit	1.75M	1.26M	2.4M	3.56M	5.72M
Selling General & Admin Expenses, Total	3.3M	2.95M	3.17M	3.3M	5.89M
Depreciation & Amortization - (IS)	106K	123K	136K	256K	227K
Other Operating Expenses	119K	117K	271K	360K	-146K
Other Operating Expenses, Total	3.53M	3.19M	3.58M	3.92M	5.97M
Operating Income	-1.78M	-1.93M	-1.18M	-363K	-255K
Interest Expense, Total	-15	-	-105	-2.65K	-2K
Interest And Investment Income	62.34K	71.62K	2.53K	39.74K	-
Net Interest Expenses	62.32K	71.62K	2.43K	37.09K	-2K
Currency Exchange Gains (Loss)	-22.15K	381K	-	93	-
Other Non Operating Income (Expenses)	-21.28K	886	6.72K	-4	2K
EBT, Excl. Unusual Items	-1.76M	-1.48M	-1.17M	-326K	-255K
Merger & Related Restructuring Charges	-	-	-	-	-312K
Gain (Loss) On Sale Of Investments	45	26.64K	-23.6K	23.6K	-
Gain (Loss) On Sale Of Assets	-65.59K	-2.39M	-69.21K	-21.95K	-
Asset Writedown	-	-	-70K	-53.48K	-
Other Unusual Items	-95.92K	2.64M	343	-60.24K	100K
EBT, Incl. Unusual Items	-1.92M	-1.2M	-1.33M	-438K	-467K
Income Tax Expense	-271K	-333K	-193K	-153K	-92K
Earnings From Continuing Operations	-1.65M	-862K	-1.14M	-285K	-375K
Net Income to Company	-1.65M	-862K	-1.14M	-285K	-375K
Net Income - (IS)	-1.65M	-862K	-1.14M	-285K	-375K
Net Income to Common Incl Extra Items	-1.65M	-862K	-1.14M	-285K	-375K
Net Income to Common Excl. Extra Items	-1.65M	-862K	-1.14M	-285K	-375K
Per Share Items
Net EPS - Basic	-0.33	-0.13	-0.18	-0.04	-0.06
Basic EPS - Continuing Operations	-0.33	-0.13	-0.18	-0.04	-0.06
Basic Weighted Average Shares Outstanding	5.02M	6.48M	6.46M	6.49M	6.7M
Net EPS - Diluted	-0.33	-0.13	-0.18	-0.04	-0.06
Diluted EPS - Continuing Operations	-0.33	-0.13	-0.18	-0.04	-0.06
Diluted Weighted Average Shares Outstanding	5.02M	6.48M	6.46M	6.49M	6.7M
Normalized Basic EPS	-0.22	-0.14	-0.11	-0.03	-0.02
Normalized Diluted EPS	-0.22	-0.14	-0.11	-0.03	-0.02
Supplemental Items
EBITDA	-1.67M	-1.81M	-1.04M	-107K	-28K
EBITA	-1.78M	-1.93M	-1.18M	-363K	-255K
EBIT	-1.78M	-1.93M	-1.18M	-363K	-255K
EBITDAR	-1.36M	-	-780K	-	252K
Total Revenues (As Reported)	6.35M	6.59M	7.07M	8.32M	9.15M
Effective Tax Rate - (Ratio)	14.09	27.88	14.47	34.96	19.7
Normalized Net Income	-1.1M	-923K	-731K	-204K	-159K
Supplemental Operating Expense Items
Net Rental Expense, Total	312K	-	263K	-	280K
Imputed Operating Lease Interest Expense	22	-	393	-	3.89K
Imputed Operating Lease Depreciation	312K	-	263K	-	276K
Maintenance & Repair Expenses, Total	-	248K	238K	-	385K

Fiscal Period: December	2016 (EUR)	2017 (EUR)	2018 (EUR)	2019 (EUR)	2020 (EUR)
Assets
Cash And Equivalents	549K	1.34M	735K	1.2M	5.12M
Short Term Investments	2.18M	2.79M	3.27M	1.61M	-
Total Cash And Short Term Investments	2.73M	4.13M	4.01M	2.81M	5.12M
Accounts Receivable, Total	2.14M	2.41M	2.32M	1.83M	2.14M
Other Receivables	623K	846K	395K	529K	444K
Total Receivables	2.76M	3.26M	2.72M	2.36M	2.59M
Inventory	378K	360K	389K	290K	238K
Prepaid Expenses	192K	158K	218K	232K	-
Other Current Assets, Total	5.53K	3	3	5.61K	-
Total Current Assets	6.07M	7.91M	7.33M	5.69M	7.95M
Gross Property Plant And Equipment	1.23M	1.27M	2.01M	2.05M	1.95M
Accumulated Depreciation	-717K	-835K	-971K	-1.22M	-1.38M
Net Property Plant And Equipment	512K	436K	1.03M	827K	572K
Long-term Investments	323K	302K	217K	230K	302K
Other Intangibles, Total	90	0	0	0	-
Loans Receivable Long-Term	-	-	-	-	-
Other Long-Term Assets, Total	689K	3	2	80	-
Total Assets	7.59M	8.65M	8.58M	6.75M	8.82M
Liabilities
Accounts Payable, Total	1.65M	1.13M	1.55M	701K	901K
Accrued Expenses, Total	1.3M	1.24M	1.33M	1.15M	-
Short-term Borrowings	163	173	-	-	-
Current Portion of Long-Term Debt	-	262K	289K	107K	-
Current Income Taxes Payable	72.15K	70.84K	-	-	1.82M
Unearned Revenue Current, Total	1.06M	1.69M	2.2M	1.92M	712K
Other Current Liabilities	30.1K	30.4K	55.5K	49.6K	1.15M
Total Current Liabilities	4.11M	4.42M	5.42M	3.93M	4.58M
Long-Term Debt	1.49M	277K	289K	182K	2.02M
Other Non Current Liabilities	703K	16.52K	80.43K	132K	54K
Total Liabilities	6.31M	4.72M	5.79M	4.24M	6.65M
Common Stock, Total	5.07M	6.54M	6.55M	6.56M	6.7M
Additional Paid In Capital	36.18M	38.22M	38.11M	5.09M	-
Retained Earnings	-39.97M	-40.83M	-41.87M	-9.14M	-9.27M
Comprehensive Income and Other	-	-	-1	-1	4.73M
Total Common Equity	1.28M	3.93M	2.79M	2.51M	2.17M
Total Equity	1.28M	3.93M	2.79M	2.51M	2.17M
Total Liabilities And Equity	7.59M	8.65M	8.58M	6.75M	8.82M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	5.02M	6.48M	6.46M	6.49M	6.65M
ECS Total Common Shares Outstanding	5.02M	6.48M	6.46M	6.49M	6.65M
Book Value / Share	0.26	0.61	0.43	0.39	0.33
Tangible Book Value	1.28M	3.93M	2.79M	2.51M	2.17M
Tangible Book Value Per Share	0.26	0.61	0.43	0.39	0.33
Total Debt	1.49M	540K	577K	289K	2.02M
Net Debt	-1.23M	-3.59M	-3.43M	-2.52M	-3.11M
Debt Equivalent Oper. Leases	2.49M	-	2.1M	-	2.24M
Equity Method Investments, Total	-	32.44K	-	-	-
Account Code - Inventory Valuation	5	5	5	5	3
Inventories - Raw Materials, Total	394K	387K	380K	298K	-
Inventories - Work In Process, Total	-	-	8.84K	-	-
Inventories - Finished Goods, Total	-	-	-	7.74K	-
Machinery, Total	1.23M	1.27M	1.88M	2.05M	1.95M
Full Time Employees	38	38	44	41	53
Accumulated Allowance for Doubtful Accounts (Supple)	-	-	-	10.85K	-

Fiscal Period: December	2016 (EUR)	2017 (EUR)	2018 (EUR)	2019 (EUR)	2020 (EUR)
Profitability
Return on Assets	-13.72	-14.86	-8.55	-2.96	-2.05
Return on Total Capital	-30.46	-33.3	-18.8	-7.36	-4.56
Return On Equity %	-78.32	-33.08	-33.9	-10.74	-16.03
Return on Common Equity	-78.32	-33.08	-33.9	-10.74	-16.03
Margin Analysis
Gross Profit Margin %	27.88	19.39	34.49	42.95	63.52
SG&A Margin	52.65	45.34	45.6	39.89	65.46
EBITDA Margin %	-26.67	-27.76	-15.01	-1.29	-0.31
EBITA Margin %	-28.36	-29.65	-16.97	-4.38	-2.83
EBIT Margin %	-28.36	-29.65	-16.97	-4.38	-2.83
Income From Continuing Operations Margin %	-26.32	-13.25	-16.4	-3.44	-4.17
Net Income Margin %	-26.32	-13.25	-16.4	-3.44	-4.17
Net Avail. For Common Margin %	-26.32	-13.25	-16.4	-3.44	-4.17
Normalized Net Income Margin	-17.54	-14.18	-10.52	-2.46	-1.77
Asset Turnover
Asset Turnover	0.77	0.8	0.81	1.08	1.16
Fixed Assets Turnover	14.64	13.73	9.46	8.9	12.87
Receivables Turnover (Average Receivables)	3.41	2.74	2.92	3.99	4.54
Inventory Turnover (Average Inventory)	14	14.22	12.16	13.92	12.44
Short Term Liquidity
Current Ratio	1.48	1.79	1.35	1.45	1.73
Quick Ratio	1.34	1.67	1.24	1.32	1.68
Days Sales Outstanding (Average Receivables)	107.36	133.02	124.91	91.49	80.7
Days Outstanding Inventory (Average Inventory)	26.14	25.67	30.01	26.21	29.43
Average Days Payable Outstanding	112.7	96.88	106.38	88.65	-
Cash Conversion Cycle (Average Days)	20.81	61.81	48.54	29.05	-
Long Term Solvency
Total Debt/Equity	116.4	13.74	20.67	11.5	92.81
Total Debt / Total Capital	53.79	12.08	17.13	10.32	48.14
LT Debt/Equity	116.39	7.06	10.33	7.24	92.81
Long-Term Debt / Total Capital	53.78	6.21	8.56	6.5	48.14
Total Liabilities / Total Assets	83.1	54.56	67.45	62.82	75.39
EBIT / Interest Expense	-119K	-	-11.23K	-137.11	-127.5
EBITDA / Interest Expense	-112K	-	-9.94K	-40.39	-14
(EBITDA - Capex) / Interest Expense	-112K	-	-9.94K	-40.39	-14
Total Debt / EBITDA	-0.89	-0.3	-0.55	-2.7	-71.96
Net Debt / EBITDA	0.74	1.99	3.29	23.55	111.04
Total Debt / (EBITDA - Capex)	-0.89	-0.3	-0.55	-2.7	-71.96
Net Debt / (EBITDA - Capex)	0.74	1.99	3.29	23.55	111.04
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	8.37	3.77	6.8	19.12	8.7
Gross Profit, 1 Yr. Growth %	61.84	-12.17	89.99	48.34	0.02
EBITDA, 1 Yr. Growth %	-24.81	7.99	-42.26	-89.75	-60
EBITA, 1 Yr. Growth %	-23.12	8.51	-38.9	-69.21	-29.75
EBIT, 1 Yr. Growth %	-23.12	8.51	-38.9	-69.21	-29.75
Earnings From Cont. Operations, 1 Yr. Growth %	7.62	-47.77	32.19	-75.01	31.58
Net Income, 1 Yr. Growth %	7.62	-47.77	32.19	-75.01	31.58
Normalized Net Income, 1 Yr. Growth %	-27.05	-16.11	-20.38	-72.15	-15.56
Diluted EPS Before Extra, 1 Yr. Growth %	9.62	-59.56	32.54	-75.1	28.82
Accounts Receivable, 1 Yr. Growth %	53.55	12.81	-3.73	-21.37	17.24
Inventory, 1 Yr. Growth %	40.82	-4.72	7.96	-25.46	-17.93
Net Property, Plant and Equip., 1 Yr. Growth %	48.28	-14.77	137.05	-20.04	-30.83
Total Assets, 1 Yr. Growth %	-11.95	13.96	-0.77	-21.38	30.74
Tangible Book Value, 1 Yr. Growth %	-56.25	206.53	-28.92	-10.2	-13.47
Common Equity, 1 Yr. Growth %	-56.28	206.51	-28.92	-10.2	-13.47
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	1.16	6.04	5.27	12.79	13.79
Gross Profit, 2 Yr. CAGR %	20.33	8.07	29.17	67.88	54.43
EBITDA, 2 Yr. CAGR %	2.08	-9.89	-21.03	-75.67	-83.62
EBITA, 2 Yr. CAGR %	2.71	-8.66	-18.58	-56.63	-53.5
EBIT, 2 Yr. CAGR %	2.71	-8.66	-18.58	-56.63	-53.5
Earnings From Cont. Operations, 2 Yr. CAGR %	25.77	-25.03	-16.91	-42.52	-42.64
Net Income, 2 Yr. CAGR %	25.77	-25.03	-16.91	-42.52	-42.64
Normalized Net Income, 2 Yr. CAGR %	11.42	-21.77	-18.46	-52.91	-53.32
Diluted EPS Before Extra, 2 Yr. CAGR %	25.14	-33.41	-26.78	-42.55	-43.67
Accounts Receivable, 2 Yr. CAGR %	3.05	31.61	4.21	-13	-3.99
Inventory, 2 Yr. CAGR %	5.36	15.83	1.42	-10.29	-21.75
Net Property, Plant and Equip., 2 Yr. CAGR %	46.1	12.42	42.14	37.68	-25.62
Total Assets, 2 Yr. CAGR %	-9.03	0.17	6.34	-11.67	1.38
Tangible Book Value, 2 Yr. CAGR %	-41.59	15.81	47.61	-20.11	-11.85
Common Equity, 2 Yr. CAGR %	-41.62	15.76	47.6	-20.11	-11.85
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	5.04	2.02	6.29	9.7	11.41
Gross Profit, 3 Yr. CAGR %	131.72	1.48	30.43	35.27	65.47
EBITDA, 3 Yr. CAGR %	-15.9	4.01	-22.31	-60.02	-75.07
EBITA, 3 Yr. CAGR %	-14.96	4.61	-20.12	-41.12	-49.07
EBIT, 3 Yr. CAGR %	-14.97	4.61	-20.12	-41.12	-49.07
Earnings From Cont. Operations, 3 Yr. CAGR %	-13.45	-6.17	-9.43	-44.33	-24.23
Net Income, 3 Yr. CAGR %	-13.45	-6.17	-9.43	-44.33	-24.23
Normalized Net Income, 3 Yr. CAGR %	-14.5	1.36	-21.43	-43	-44.22
Diluted EPS Before Extra, 3 Yr. CAGR %	-18.61	-14.12	-16.24	-48.89	-25.08
Accounts Receivable, 3 Yr. CAGR %	8.73	6.2	18.58	-5.13	-3.9
Inventory, 3 Yr. CAGR %	17.27	1.89	13.15	-8.47	-12.89
Net Property, Plant and Equip., 3 Yr. CAGR %	46.77	22.08	44.16	17.34	9.45
Total Assets, 3 Yr. CAGR %	9.48	-1.93	-0.14	-3.84	0.66
Tangible Book Value, 3 Yr. CAGR %	23.25	1.51	-1.58	25.07	-17.95
Common Equity, 3 Yr. CAGR %	22.84	1.47	-1.61	25.07	-17.95
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	6.14	6.48	5.13	6.2	9.23
Gross Profit, 5 Yr. CAGR %	94.06	56.82	76.35	24.11	39.54
EBITDA, 5 Yr. CAGR %	-6.74	-4.93	-17.99	-41.83	-58.32
EBITA, 5 Yr. CAGR %	-5.83	-4	-16.43	-26.44	-35.66
EBIT, 5 Yr. CAGR %	-5.83	-4	-16.43	-26.44	-35.66
Earnings From Cont. Operations, 5 Yr. CAGR %	-4.15	-12.96	-14.85	-22.87	-24.55
Net Income, 5 Yr. CAGR %	-4.15	-12.96	-14.85	-22.87	-24.55
Normalized Net Income, 5 Yr. CAGR %	-6.04	-8.38	-16.1	-25.47	-36.2
Diluted EPS Before Extra, 5 Yr. CAGR %	-9.47	-19.76	-21.98	-26.88	-28.53
Accounts Receivable, 5 Yr. CAGR %	25.61	13.13	6.9	-1.94	8.98
Inventory, 5 Yr. CAGR %	16.04	12.73	10.65	-3.17	-2.37
Net Property, Plant and Equip., 5 Yr. CAGR %	19.12	15.64	44.9	28.09	10.63
Total Assets, 5 Yr. CAGR %	1.73	1.95	8.21	-5.95	0.46
Tangible Book Value, 5 Yr. CAGR %	-16.14	3.96	32.47	-7.76	-5.82
Common Equity, 5 Yr. CAGR %	-16.14	3.96	32.2	-7.79	-5.84

Fiscal Period: December	2014 (EUR)	2015 (EUR)	2016 (EUR)	2017 (EUR)	2018 (EUR)	2019 (EUR)	2020 (EUR)
Supplemental Items
Change In Net Working Capital			409K	389K	-1.42M	871K	-832K